Article

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

2021-07-22

Abstract excerpt

Although cancer immunotherapy with PD-(L)1 blockade is now routine treatment for patients with lung cancer, remarkably little is known about acquired resistance. We examined 1,201 patients with NSCLC treated with PD-(L)1 blockade to clinically characterize acquired resistance, finding it to be common (occurring in more than 60% of initial responders), with persistent but diminishing risk over time, and with distin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 843bdd9d-5197-518f-8cad-da7780d609ec
DOI: 10.1101/2021.07.21.452854

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerDOI 10.1101/2021.07.21.452854Read

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerSemantic proximity Read

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.Semantic proximity Read

Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and <i>MET</i> amplificationSemantic proximity Read

Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapySemantic proximity Read

AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy.Semantic proximity Read

The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancerSemantic proximity Read

Evolution of resistance to KRAS <sup>G12C</sup> inhibitor in a non-small cell lung cancer responderSemantic proximity Read

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studySemantic proximity Read

Genomic and Transcriptomic Correlates of Response to Tarlatamab in Small Cell Lung CancerSemantic proximity Read

Evolution of resistance to KRASG12C inhibitor in a non-small cell lung cancer responderSemantic proximity Read

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insightsSemantic proximity Read

Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cellsSemantic proximity Read